Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
about
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
description
A clinical trial related to cancer immunotherapy, retrieved from clinicaltrials.gov
@en
klinisch onderzoek
@nl
name
Rituximab, Yttrium Y 90 Ibritu ...... ously Treated Multiple Myeloma
@en
Rituximab, Yttrium Y 90 Ibritu ...... ously Treated Multiple Myeloma
@nl
type
label
Rituximab, Yttrium Y 90 Ibritu ...... ously Treated Multiple Myeloma
@en
Rituximab, Yttrium Y 90 Ibritu ...... ously Treated Multiple Myeloma
@nl
prefLabel
Rituximab, Yttrium Y 90 Ibritu ...... ously Treated Multiple Myeloma
@en
Rituximab, Yttrium Y 90 Ibritu ...... ously Treated Multiple Myeloma
@nl
P1050
P3098
NCT00477815